Nanoviricides (NNVC) Interest Expenses (2013 - 2025)
Nanoviricides (NNVC) posted Interest Expenses of $4.0 for Q3 2025, down 93.55% sequentially from $62.0 in Q1 2025, and down 94.52% YoY from $73.0 in Q3 2024.
Nanoviricides (NNVC) Interest Expenses (2013 - 2025) Analysis & Trends
Nanoviricides has reported Interest Expenses for 13 years, with the latest figure at $4.0 in Q3 2025.
- Quarterly Interest Expenses fell 94.52% year-over-year to $4.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $4.0 (down 94.52% YoY) and the FY2025 annual result came in at $27271.0, down 45.25% from the prior year.
- Interest Expenses fell to $4.0 in Q3 2025 per NNVC's latest filing, from $62.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $36493.0 in Q3 2023 and troughed at $4.0 in Q3 2025.
- A 5-year average of $4306.6 and a median of $868.0 in 2021 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2023 and 2024: Interest Expenses soared 14064.89% in 2023, then plunged 99.8% in 2024.
- Over 5 years, Interest Expenses stood at $95.0 in 2021, then decreased by 1.05% to $94.0 in 2022, then jumped by 14064.89% to $13315.0 in 2023, then plunged by 98.88% to $149.0 in 2024, then plunged by 97.32% to $4.0 in 2025.
- According to Business Quant data, Interest Expenses over the past three periods registered $4.0, $62.0, and $149.0 for Q3 2025, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 82.05 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 20.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 93.62 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -4.89 Mn |
| 10 | Nanoviricides | 28.31 Mn | 25.10 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 4.00 |
| Sep 30, 2025 | 4.00 |
| Mar 31, 2025 | 62.00 |
| Mar 31, 2025 | 62.00 |
| Dec 31, 2024 | 149.00 |
| Dec 31, 2024 | 149.00 |
| Sep 30, 2024 | 73.00 |
| Sep 30, 2024 | 73.00 |
| Dec 31, 2023 | 13,315.00 |
| Dec 31, 2023 | 13,315.00 |
| Sep 30, 2023 | 36,493.00 |
| Sep 30, 2023 | 36,493.00 |
| Dec 31, 2022 | 94.00 |
| Dec 31, 2022 | 94.00 |
| Sep 30, 2022 | 844.00 |
| Sep 30, 2022 | 844.00 |
| Jun 30, 2022 | 1,678.00 |
| Jun 30, 2022 | 1,678.00 |
| Mar 31, 2022 | 2,502.00 |
| Mar 31, 2022 | 2,502.00 |